Empr.com: FDA Fast-Tracks Treatment for Autism Spectrum Disorder

L1-79 is a tyrosine hydroxylase inhibitor

Yamo announced that the Food and Drug Administration (FDA) has granted Fast Track designation to L1-79, a new drug candidate intended to mitigate the socialization and communication symptoms in patients with autism spectrum disorder (ASD). There are currently no approved pharmacological treatments that address

Read the full article at the original source

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.